Brand names: Ambien, Ambien CR, Edluar
Drug class: Non-benzodiazepine Hypnotics

Medically reviewed by Drugs.com on Jun 10, 2024. Written by ASHP.

Introduction

Imidazopyridine-derivative sedative and hypnotic; type A GABA (GABA_A)-receptor positive modulator; structurally unrelated to benzodiazepines and other sedatives and hypnotics.

Uses for Zolpidem

Insomnia

Conventional tablets and sublingual tablets (5 and 10 mg) are used for short-term management of insomnia characterized by difficulties with sleep initiation. Decreases sleep latency in patients with chronic or transient insomnia; no substantial evidence of diminished effectiveness during the end of each night’s use (early morning insomnia) despite short half-life.

Extended-release tablets are used for short-term management of insomnia characterized by difficulty with sleep onset or sleep maintenance. May not be an appropriate treatment choice for patients (men or women) who need to drive or perform activities that require full alertness the next morning.

Sublingual tablets (1.75 and 3.5 mg) are used as needed for management of insomnia when middle-of-the-night awakening is followed by difficulty returning to sleep; use only when ≥4 hours remain before planned time of awakening.

Psychological and behavioral interventions are recommended as initial treatment for insomnia according to the American Academy of Sleep Medicine (AASM) and American College of Physicians (ACP) guidelines. When pharmacologic therapy is indicated, choice of agent should be directed by symptoms, treatment goals, past treatment response, patient preference, drug cost and availability, comorbid conditions/contraindications, concomitant drug therapy/interactions, and potential adverse effects. Zolpidem is among several agents recommended for treatment of sleep onset or sleep maintenance insomnia. The lowest effective dosage and short-term treatment (4–5 weeks) is recommended.

Zolpidem Dosage and Administration

General

Pretreatment Screening

• Consider the risk of respiratory depression prior to use of zolpidem in patients with respiratory impairment, including those with sleep apnea or myasthenia gravis or in those receiving concomitant opiates or other CNS depressants.

Patient Monitoring

• Monitor for excessive CNS depression.

• Monitor for abnormal thinking and behavioral changes; carefully and immediately evaluate any new and concerning behavioral sign or symptom.

Other General Considerations

• Reevaluate patient if zolpidem is to be used for more than 2–3 weeks.

• Consider gradual dosage reduction (e.g., over several nights) when discontinuing therapy.

Administration

Administer orally (as conventional tablets or extended-release tablets) or sublingually (as sublingual tablets).

Oral Administration

Do not administer with or immediately after a meal in order to facilitate onset of sleep.

Conventional Tablets

Administer only once per night immediately before bedtime, at least 7–8 hours before planned time of awakening.

Extended-release Tablets

Administer only once per night immediately before bedtime, at least 7–8 hours before planned time of awakening.

Swallow extended-release tablets whole; do not divide, crush, or chew.

Sublingual Administration

Do not administer with or immediately after a meal in order to facilitate onset of sleep.

Sublingual Tablets (5 and 10 mg)

Administer only once per night immediately before bedtime, at least 7–8 hours before planned time of awakening.

Place tablet under tongue, where it will disintegrate. Do not swallow or administer tablet with water.

Sublingual Tablets (1.75 and 3.5 mg)

Administer in bed, only once per night as needed if middle-of-the-night awakening is followed by difficulty returning to sleep, and only if ≥4 hours remain before planned time of awakening.

Place tablet under tongue and allow to disintegrate completely before swallowing. Do not swallow tablet whole.

Remove tablet from pouch just prior to administration.

Dosage

Available as zolpidem tartrate; dosage expressed in terms of the salt.

Use the lowest effective dosage and shortest duration of treatment possible. Do not use for extended duration without reevaluation of patient status; risk of abuse and dependence increases with duration of treatment.

Adults

Insomnia

Difficulty with Sleep Initiation

Oral (Conventional Tablets) or Sublingual (5 and 10 mg Sublingual Tablets)

Women: Initially, single 5-mg dose.

Men: Initially, single 5- or 10-mg dose.

If 5 mg is not effective in men or women, may increase dose to 10 mg.

In some patients, higher morning blood concentrations following a 10-mg dose increase risk of next-day impairment of driving and other activities requiring full alertness.

Initial doses for women and men differ because clearance is slower in women.

Difficulty with Sleep Initiation or Sleep Maintenance

Oral (Extended-release Tablets)

Women: Initially, single 6.25-mg dose.

Men: Initially, single 6.25- or 12.5-mg dose.

If 6.25 mg is not effective in men or women, may increase dose to 12.5 mg.

In some patients, higher morning blood concentrations following a 12.5-mg dose increase risk of next-day impairment of driving and other activities requiring full alertness.

Initial doses for women and men differ because clearance is slower in women.

Middle-of-the-Night Awakening

Sublingual (1.75 and 3.5 mg Sublingual Tablets)

Women: 1.75 mg.

Men: 3.5 mg.

Doses for women and men differ because clearance is slower in women.

Men or women receiving concomitant CNS depressant: 1.75 mg.

Prescribing Limits

Adults

Insomnia

Difficulty with Sleep Initiation

Oral (Conventional Tablets) or Sublingual (5 and 10 mg Sublingual Tablets)

Maximum 10 mg once daily immediately before bedtime.

Difficulty with Sleep Initiation or Sleep Maintenance

Oral (Extended-release Tablets)

Maximum 12.5 mg once daily immediately before bedtime.

Middle-of-the-Night Awakening

Sublingual (1.75 and 3.5 mg Sublingual Tablets)

Women: Maximum 1.75 mg once per night.

Men: Maximum 3.5 mg once per night.

Special Populations

Hepatic Impairment

Prolonged elimination.

Conventional tablets In patients with mild or moderate hepatic impairment, 5 mg once daily immediately before bedtime. Avoid use in patients with severe hepatic impairment.

Extended-release tablets: In patients with mild or moderate hepatic impairment, 6.25 mg once daily immediately before bedtime. Avoid use in patients with severe hepatic impairment.

Sublingual tablets for insomnia characterized by difficulties with sleep initiation: 5 mg once daily immediately before bedtime.

Sublingual tablets for middle-of-the-night awakening: 1.75 mg only once per night if needed.

Renal Impairment

Possible pharmacokinetic alterations. Manufacturers state that dosage adjustment is not necessary; some clinicians recommend that dosage reduction be considered.

Geriatric Patients

Possible increased sensitivity to sedatives and hypnotics.

Conventional tablets: 5 mg once daily immediately before bedtime.

Extended-release tablets: 6.25 mg once daily immediately before bedtime.

Sublingual tablets for insomnia characterized by difficulties with sleep initiation: 5 mg once daily immediately before bedtime.

Sublingual tablets for middle-of-the-night awakening: In men and women >65 years of age, 1.75 mg only once per night if needed.

Debilitated Patients

Possible increased sensitivity to sedatives and hypnotics.

Conventional tablets: 5 mg once daily immediately before bedtime.

Extended-release tablets: 6.25 mg once daily immediately before bedtime.

Sublingual tablets for insomnia characterized by difficulties with sleep initiation: 5 mg once daily immediately before bedtime.

Cautions for Zolpidem

Contraindications

• History of a complex sleep behavior while taking eszopiclone, zaleplon, or zolpidem.

• Known hypersensitivity to zolpidem.

Warnings/Precautions

Warnings

Complex Sleep Behaviors

Complex sleep behaviors, in which patients engage in activities while they are not fully awake, reported in patients taking hypnotic-sedative agents; some cases may result in serious injuries and/or death. (See Boxed Warning.) Such behaviors may include sleepwalking, sleep driving (i.e., driving while not fully awake after ingesting a sedative-hypnotic drug, with no memory of the event), and engaging in other activities (e.g., making phone calls, preparing and eating food).

Falls with serious injuries such as intracranial hemorrhages, vertebral fractures, and hip fractures as well as fatal falls, self-injuries, accidental overdoses, hypothermia, suicide attempts and apparent completed suicides, fatal motor vehicle collisions, gunshot wounds, carbon monoxide poisoning, drowning or near drowning, burns, and homicide have been reported to FDA.

Reported in patients with or without a history of such behaviors and even at the lowest recommended dosages or after just one dose.

Can occur when these drugs are taken alone or with alcohol or other CNS depressants.

Discontinue zolpidem immediately if a complex sleep behavior occurs.

Other Warnings and Precautions

CNS Depression and Next-day Impairment

CNS depressant; may impair daytime function in some patients even when used as prescribed.

Zolpidem blood concentrations >50 ng/mL may impair driving to a degree that increases risk of a motor vehicle accident. Concentrations >50 ng/mL reported at 8 hours after a dose in 15% of women and 3% of men receiving 10 mg (as conventional tablets); in 33% of women and 25% of men receiving 12.5 mg (as extended-release tablets); and in 15% of nongeriatric women, 5% of nongeriatric men, and 10% of both geriatric men and women receiving 6.25 mg (as extended-release tablets). Some patients had concentrations ≥90 or ≥100 ng/mL. Because of these findings, bedtime dosages currently recommended by the manufacturers and FDA are lower than original labeled dosages.

Impaired driving reported when driving test administered to healthy individuals <4 hours after a 3.5-mg sublingual dose; potential driving impairment at 4 hours after recommended 1.75-mg dose in women or 3.5-mg dose in men cannot be completely excluded.

Use smallest effective dose to decrease potential risk of next-day impairment.

Monitor patients for excessive CNS depression; however, impairment may occur in the absence of symptoms and may not be reliably detected by ordinary clinical examination (i.e., formal psychomotor testing may be required).

Concurrent use of other CNS depressants (e.g., alcohol, benzodiazepines, opiates, tricyclic antidepressants) increases risk of CNS depression. Dosage adjustments of zolpidem and concurrent CNS depressants may be necessary.

Concomitant use with other sedatives and hypnotics (including other zolpidem-containing preparations and OTC preparations used to treat insomnia [e.g., diphenhydramine, doxylamine succinate]) at bedtime or in middle of the night is not recommended.

Women appear to be more susceptible to next-day psychomotor impairment because zolpidem clearance is slower in women than in men.

Administration as extended-release tablets increases risk of next-day impairment. Extended-release zolpidem may not be an appropriate treatment choice for patients who need to drive or perform activities that require full alertness the next morning. Drug concentrations may remain high enough the next day to impair performance.

Risk of next-day impairment is increased if preparations intended for bedtime administration (e.g., conventional or extended-release tablets, 5- or 10-mg sublingual tablets) are administered with less than 7–8 hours of sleep time remaining, if preparations intended for middle-of-the-night administration (1.75- or 3.5-mg sublingual tablets) are administered with <4 hours of sleep time remaining, if higher than recommended dose is administered, or if used concomitantly with other CNS depressants (including alcohol) or drugs that increase zolpidem concentrations.

Warn vehicle drivers and machine operators that, as with other hypnotics, there may be a possible risk of adverse reactions including drowsiness, prolonged reaction time, dizziness, sleepiness, blurred/double vision, reduced alertness, and impaired driving the morning after therapy. In order to minimize this risk a full night of sleep (7–8 hours) is recommended.

Drowsiness and decreased levels of consciousness associated with zolpidem may result in an increased risk of falls, particularly in geriatric patients.

Adequate Patient Evaluation

Insomnia may be a manifestation of an underlying physical and/or psychiatric disorder; carefully evaluate patient before providing symptomatic treatment.

Failure of insomnia to remit after 7–10 days of treatment, worsening of insomnia, or emergence of new thinking or behavioral abnormalities may indicate the presence of an underlying psychiatric and/or medical condition that requires evaluation.

Severe Hypersensitivity Reactions

Angioedema involving the tongue, glottis, or larynx reported following initial or subsequent doses of sedative and hypnotic drugs, including zolpidem; may result in airway obstruction and death. Anaphylaxis also reported.

Do not rechallenge with the drug if angioedema occurs.

Abnormal Thinking and Behavioral Changes

Abnormal thinking and behavioral changes (e.g., decreased inhibition, aggressiveness, uncharacteristic extroversion, bizarre behavior, agitation, depersonalization, visual and auditory hallucinations) reported in patients receiving sedative and hypnotic drugs, including zolpidem. Amnesia, anxiety, and other neuropsychiatric symptoms may occur. Cases of delirium also reported.

Carefully and immediately evaluate any new and concerning behavioral sign or symptom.

Use in Patients with Depression

Worsening of depression and suicidal thoughts and actions (including completed suicides) reported in primarily depressed patients receiving sedatives and hypnotics. Suicidal tendencies may be present; intentional overdosage more frequent in such patients. Protective measures may be required. Prescribe and dispense drug in the smallest feasible quantity.

Respiratory Depression

No respiratory depressant effects reported following 10-mg doses in healthy individuals or patients with mild to moderate COPD; however, decreased oxygen saturation reported in patients with mild to moderate sleep apnea. Respiratory insufficiency reported, mostly in patients with preexisting respiratory impairment.

Use with caution in patients with compromised respiratory function and in patients receiving concomitant opiates or other CNS depressants; sedatives and hypnotics may depress respiratory drive.

Consider risk of respiratory depression prior to use in patients with respiratory impairment (e.g., sleep apnea, myasthenia gravis) or in those receiving concomitant opiates or other CNS depressants.

Precipitation of Hepatic Encephalopathy

Precipitation of hepatic encephalopathy reported in patients with hepatic insufficiency receiving drugs affecting GABA receptors (e.g., zolpidem tartrate). In addition, zolpidem is eliminated more slowly in patients with hepatic insufficiency.

Manufacturer of conventional and extended-release tablets states to avoid use in patients with severe hepatic impairment.

Withdrawal Effects

Signs and symptoms of withdrawal reported following rapid dosage reduction or abrupt discontinuance; monitor patients for tolerance and dependence.

Abuse Potential

May lead to development of physical and/or psychological dependence; risk of dependence increases with dose and duration of treatment and is greater in patients with a history of alcohol or drug abuse.

Zolpidem tartrate 40 mg and diazepam 20 mg (as single doses) had similar effects in former drug abusers; effects of zolpidem tartrate 10 mg and placebo were difficult to distinguish. Monitor patients for abuse.

Increased risk for misuse and abuse of and addiction to zolpidem in patients with current or past history of addiction to or abuse of drugs or alcohol; use with extreme caution in such patients.

Do not use for extended duration without reevaluation of patient status; risk of abuse and dependence increases with duration of treatment.

Specific Populations

Pregnancy

Available evidence shows no clear association between zolpidem use during pregnancy and major birth defects. No adverse fetal developmental effects observed in animal reproduction studies.

Zolpidem crosses the placenta and may cause respiratory depression and sedation in neonates. Monitor neonates exposed to zolpidem during pregnancy and labor for signs of excess sedation, hypotonia, and respiratory depression and treat as clinically indicated.

Lactation

Distributed into milk in small amounts; excess sedation reported in nursing infants. Effects of zolpidem on milk production not known.

Consider the developmental and health benefits of breast-feeding along with the mother’s clinical need for zolpidem and any potential adverse effects on the breast-fed infant from the drug or underlying maternal condition.

Monitor infants exposed to zolpidem through breast-feeding for excess sedation, hypotonia, and respiratory depression.

Nursing women may consider interrupting breast-feeding and pumping and discarding breast milk during treatment and for 23 hours after administration of zolpidem to minimize drug exposure to a breast-fed infant.

Pediatric Use

Not recommended in pediatric patients.

Safety and efficacy not established in pediatric patients <18 years of age. Dizziness, headache, and hallucinations reported.

Geriatric Use

Pharmacokinetic changes in geriatric patients compared with younger adults.

Potential increased sensitivity to zolpidem. Adverse effects tend to be dose-related, particularly in geriatric patients. Adverse effect profile in patients ≥65 years of age receiving 6.25-mg dose (as extended-release tablets) similar to that in younger adults receiving 12.5-mg dose.

Use reduced dose to minimize adverse effects related to impaired motor and/or cognitive performance and unusual sensitivity to sedative and hypnotic drugs. Sedatives may cause confusion and oversedation in geriatric patients; observe closely. Geriatric patients are at a higher risk of falls related to drowsiness and CNS depression.

Hepatic Impairment

Prolonged elimination; reduce dose in patients with mild or moderate hepatic impairment. Manufacturer states to avoid use of zolpidem conventional or extended-release tablets in patients with severe hepatic impairment; drug may contribute to hepatic encephalopathy.

Renal Impairment

Possible pharmacokinetic alterations. Manufacturers state that dosage adjustment is not necessary; however, some clinicians recommend that dosage reduction be considered.

Common Adverse Effects

Zolpidem tartrate conventional tablets generally are well tolerated at recommended doses (i.e., up to 10 mg). Adverse effects of the drug tend to be dose-related, particularly in geriatric patients and at doses exceeding those recommended. The most common adverse reactions with zolpidem conventional tablets when used in the short-term (<10 nights) include drowsiness, dizziness, and diarrhea; common adverse reactions reported with long-term use (28–35 nights) of the conventional tablets include dizziness and drugged feeling.

Adverse effects of zolpidem tartrate as extended-release tablets tend to be dose-related, particularly for certain adverse nervous system and GI effects. The most common adverse effects of zolpidem tartrate as extended-release tablets (occurring in >10% of adult patients) include headache, next-day somnolence, and dizziness.

The incidence of adverse effects in patients receiving zolpidem tartrate as 1.75- or 3.5-mg sublingual tablets were headache, fatigue, and nausea.

Drug Interactions

Metabolized principally by CYP3A4 and to a lesser extent by CYP1A2 and CYP2D6.

Drugs Affecting Hepatic Microsomal Enzymes

Some drugs that inhibit CYP3A may increase systemic exposure to zolpidem. Consider decreasing zolpidem dosage if used concomitantly with a potent CYP3A4 inhibitor.

Some drugs that induce CYP3A may decrease systemic exposure to zolpidem. Concomitant use with potent CYP3A4 inducers not recommended.

Effect of inhibitors or inducers of other CYP isoenzymes on pharmacokinetics (e.g., systemic exposure) of zolpidem not known.

Specific Drugs

Zolpidem Pharmacokinetics

Absorption

Bioavailability

Conventional tablets: Rapidly absorbed from GI tract following oral administration, with peak plasma concentrations attained in about 1.6 hours. Absolute bioavailability is about 70%.

Extended-release tablets: Exhibit biphasic absorption characteristics; rapid initial absorption following oral administration (similar to conventional tablets), but with extended plasma concentrations beyond 3 hours after administration. Peak plasma concentrations are attained in about 1.5 hours.

Sublingual tablets (5 and 10 mg): Bioequivalent to conventional tablets with respect to peak concentration and AUC. Rapidly absorbed, with peak plasma concentrations attained in about 82 minutes.

Sublingual tablets (1.75 and 3.5 mg): Rapidly absorbed, with peak plasma concentrations attained in about 35–75 minutes.

Food

Conventional tablets: Food decreases AUC by 15%, decreases peak plasma concentration by 25%, and prolongs time to peak plasma concentration by 60%.

Extended-release tablets: Food decreases AUC by 23%, decreases peak plasma concentration by 30%, and prolongs time to peak plasma concentration by about 2 hours (from 2 hours to 4 hours).

Sublingual tablets (5 and 10 mg): Food decreases AUC by 20%, decreases peak plasma concentration by 31%, and prolongs time to peak plasma concentration by 28% (from 82 minutes to 105 minutes).

Sublingual tablets (1.75 and 3.5 mg): Food decreases AUC by 19%, decreases peak plasma concentration by 42%, and prolongs time to peak plasma concentration to nearly 3 hours.

Plasma Concentrations

Blood concentrations >50 ng/mL may impair driving to a degree that increases risk of a motor vehicle accident. (See CNS Depression and Next-day Impairment under Cautions.)

Special Populations

Zolpidem exposure is greater in women than in men receiving the same dose. Peak concentration and AUC are increased by 45% (for immediate-release formulation) or by 50 and 75%, respectively (for extended-release tablets), in women compared with men; concentrations 6–12 hours after a dose of extended-release zolpidem are 2–3 times higher in women than in men.

Zolpidem exposure is greater in geriatric patients than in younger adults receiving the same dose. Peak concentration and AUC are increased by 50 and 64%, respectively (for conventional tablets), and by 34 and 30%, respectively (for 3.5-mg sublingual tablets), in geriatric individuals compared with younger adults. Peak concentrations and AUC are lower in geriatric individuals receiving 1.75-mg dose than in younger adults receiving 3.5-mg dose.

In patients with chronic hepatic impairment, peak plasma concentration and AUC (for conventional tablets) are 2 and 5 times higher, respectively, than in healthy individuals. Extended-release tablets not studied to date in patients with hepatic impairment.

Distribution

Extent

Distributed into milk in small amounts.

Plasma Protein Binding

Approximately 92–93%.

Elimination

Metabolism

Metabolized in the liver via oxidation and hydroxylation, principally by CYP3A4 and to a lesser extent by CYP1A2 and CYP2D6. No active metabolites.

Elimination Route

Excreted principally in urine as inactive metabolites.

Half-life

Approximately 2.5–3 hours.

Special Populations

Eliminated more slowly in women than in men; lower doses recommended for women since use of same dose in women and men would result in greater drug exposure and increased susceptibility to next-day impairment in women. In geriatric patients, clearance is similar in men and women, and dosage is not gender specific.

In geriatric patients receiving zolpidem as conventional or extended-release tablets, half-life is 2.9 hours. Half-life in geriatric patients reportedly is increased by 32% (for conventional tablets) or unchanged (for 1.75 and 3.5 mg sublingual tablets) compared with younger adults.

In patients with cirrhosis receiving zolpidem as conventional tablets, half-life is about 9.9 hours. Extended-release tablets not studied to date in patients with hepatic impairment.

In nondialyzed patients with chronic renal disease and in patients undergoing periodic dialysis, slower elimination rates reported with IV zolpidem (not commercially available in the US). No substantial pharmacokinetic alterations reported with oral zolpidem in patients with end-stage renal failure undergoing hemodialysis. Extended-release tablets not studied to date in patients with renal impairment.

Not removed by hemodialysis.

Stability

Storage

Oral

Conventional Tablets

20–25°C.

Extended-release Tablets

15–25°C (may be exposed to temperatures up to 30°C).

Sublingual

Sublingual Tablets (5 and 10 mg)

20–25°C. Protect from light and moisture.

Sublingual Tablets (1.75 and 3.5 mg)

20–25°C (may be exposed to 15–30°C). Protect from moisture.

Store tablet in pouch until just prior to administration.

Actions

• Interacts with the CNS GABA-benzodiazepine-chloride ionophore receptor complex.

• Therapeutic effects in short-term treatment of insomnia thought to occur through binding to the benzodiazepine site of α₁ subunit containing GABA A receptors, increasing frequency of chloride channel opening and resulting in inhibition of neuronal excitation.

• Selectivity for the type 1 benzodiazepine (BZ₁) receptor not absolute, but may account for the decreased muscle relaxant, anxiolytic, and anticonvulsant effects compared with benzodiazepines reported in animal studies, as well as the preservation of deep sleep (stages 3 and 4) reported in human studies.

Advice to Patients

• Provide patients with a copy of the medication guide.

• Inform patients and their families of the benefits and risks of zolpidem therapy.

• Advise all patients of the potential for next-day impairment, that the risk is increased if dosing instructions are not carefully followed, and that impairment may be present despite feeling fully awake.

• Advise patients that drowsiness and decreased consciousness may increase the risk of falls in some patients.

• Advise patients to administer immediate-release zolpidem preparations intended for bedtime administration (conventional tablets, 5- and 10-mg sublingual tablets) immediately before getting into bed, at least 7–8 hours before being active again. Wait ≥8 hours after taking the drug before driving or engaging in other activities requiring full mental alertness.

• Advise patients to administer extended-release zolpidem immediately before getting into bed, at least 7–8 hours before being active again. Avoid driving or engaging in other activities requiring complete mental alertness the day after taking this preparation.

• Advise patients to administer the 1.75- or 3.5-mg sublingual tablets in bed, only once per night as needed, if middle-of-the-night awakening is followed by difficulty returning to sleep, and only if ≥4 hours remain before planned time of awakening. Wait ≥4 hours after taking this preparation and until feeling fully awake before driving or engaging in other activities requiring full mental alertness.

• Risk of serious injury and/or death resulting from complex sleep behaviors (e.g., sleep-walking, sleep-driving, preparing and eating food, making phone calls, or having sex while not being fully awake). Advise patients to discontinue zolpidem and notify a clinician immediately if an episode of complex sleep behavior occurs during therapy, even if it did not result in serious injury.

• Potential risk of abnormal thinking and behavioral changes; advise patients to immediately inform their clinician if any such changes occur.

• Advise patients to immediately inform their clinician of any suicidal thoughts or memory impairment.

• Potential risk of severe anaphylactic and anaphylactoid reactions; advise patients to immediately seek medical attention if manifestations of such reactions occur.

• Instruct patients to take zolpidem only as prescribed; do not increase dosage unless otherwise instructed by a clinician; inform clinician if the drug is not effective.

• Risk of withdrawal symptoms following abrupt discontinuance or rapid reduction in dosage. Advise patients to inform their clinician of any tolerance or dependence/withdrawal symptoms.

• Advise patients to not take zolpidem with or immediately after a meal.

• Instruct patients to take zolpidem sublingual tablet (5 or 10 mg) under the tongue and allow it to disintegrate; do not swallow or take with water.

• Instruct patients to place zolpidem sublingual tablet (1.75 or 3.5 mg) under the tongue and allow it to disintegrate completely before swallowing; do not swallow whole. Remove the tablet from the pouch just prior to dosing.

• Advise patients to inform their clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, and any concomitant illnesses, particularly depression.

• Advise patients to not take zolpidem after consuming alcohol in the evening or before bedtime. Instruct patients to avoid concurrent use of other sedative and hypnotic drugs used to treat insomnia (including OTC preparations such as diphenhydramine or doxylamine succinate) or CNS depressants during therapy unless otherwise instructed by a clinician. Inform patients and caregivers that potentially serious additive effects may occur if zolpidem is used with opiates and not to use such drugs concomitantly with zolpidem unless supervised by a clinician.

• Advise women to inform their clinician if they are or plan to become pregnant or plan to breast-feed. Advise patients that use of zolpidem late in the third trimester may cause respiratory depression and sedation in neonates. Advise mothers who used zolpidem during the late third trimester of pregnancy to monitor neonates for signs of excess sleepiness, breathing difficulties, or limpness.

• Advise nursing women to monitor infants for increased sleepiness, breathing difficulties, or limpness and to seek immediate medical care if such signs occur. A lactating woman may consider pumping and discarding breast milk during treatment and for 23 hours after zolpidem administration to minimize drug exposure to a breast-fed infant.

• Inform patients of other important precautionary information. (See Cautions.)

Additional Information

The American Society of Health-System Pharmacists, Inc. represents that the information provided in the accompanying monograph was formulated with a reasonable standard of care, and in conformity with professional standards in the field. Readers are advised that decisions regarding use of drugs are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and that the information contained in the monograph is provided for informational purposes only. The manufacturer’s labeling should be consulted for more detailed information. The American Society of Health-System Pharmacists, Inc. does not endorse or recommend the use of any drug. The information contained in the monograph is not a substitute for medical care.

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

Subject to control under the Federal Controlled Substances Act of 1970 as a schedule IV (C-IV) drug.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Reload page with references included

Frequently asked questions

• What are the strongest sleeping pills?
• Why am I unable to sleep after taking Ambien?
• Quviviq vs. Ambien: How do they compare?
• Is Ambien safe for long-term use?
• Ambien: What are 11 Things You Need to Know?
• Is Ambien a benzo?
• Is Ambien addictive?
• Is “Ambien-Tweeting” or "Sleep-Tweeting" a Thing?
• What is this pill? Tannish peach color, elliptical, marked 10 MG and 5 dots in a small box?

View more FAQ

Medical Disclaimer